TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02687503

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Probiotic
Description: All children will receive a daily dose of probiotic (10⁹ cfu of L.acidophilus NCFM and B. lactis, Bi-07), a commercially available probiotic. Parents will give probiotic in 1 ounce of milk or water once a day for 30 days in an open label fashion.
Study: NCT03976310

Intervention type: DRUG
Group type: OTHER
Intervention: 48 weeks of Benralizumab
Description: Benralizumab is administered for 48 weeks (week 0 to week 48) every 4 weeks for the first 3 injections (30 mg sc per injection), and then every 8 weeks for the following 5 injections.

Intervention type: OTHER
Group type: OTHER
Intervention: Computed tomography
Description: Computed tomography of the thorax is performed at the beginning (week 0), middle (week 24) and towards the end (week 48) of Benralizumab therapy. A sinus scan is also added on weeks 0 and 48.
Study: NCT01426620

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry powder
Description: The intervention consists of 2-3 packages (15 grams per package) of lyophilized blueberry powder, taken daily after mixing with natural yogurt, milk, water, or juice in combination with set dosage of docetaxel (35 milligrams per meter squared) administered intravenously every week for 4 cycles, 21-day cycles.
Study: NCT01781611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended release dipyridamole 200mg/aspirin 25mg
Description: one tablet twice daily for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 81mg aspirin
Description: half a tablet twice daily for 24 weeks
Study: NCT03732898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel Programming (nDBS)
Description: The commercial CP installed with the investigational DBS programming software will be used to set up Novel Programming (nDBS) therapy on the IPG.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Programming (cDBS)
Description: The commercial CP installed with commercial software will be used to set up standard cDBS therapy on the IPG.
Study: NCT00951860

Intervention type: OTHER
Intervention: Autonomic Nervous System activity
Description: Autonomic activity measured at birth and at 6, 12, 18 and 24 months is represented by time-domain indices (SDNN index, SDANN, pNN50) and frequency- domain indices(PTOT, VLF, LF, HF, ratio LF / HF, LFnu, HFnu), which reflect the short-term variability (parasympathetic branch) and medium term (ortho and parasympathetic branch) of the vegetative balance. This subtle technical assessment of autonomic functioning has been validated in the literature for two decades
Study: NCT04572490

Intervention type: DIAGNOSTIC_TEST
Intervention: periapical radiograph
Description: alveolar bone loss measurement on standardized parallel periapical radiograph

Intervention type: DIAGNOSTIC_TEST
Intervention: periapical radiograph
Description: alveolar bone loss measurement on standardized parallel periapical radiograph
Study: NCT02364453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PACAP38
Description: Giving doses of 4, 6 or 8 pg/kg/min on three separate trial days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PACAP38
Description: Giving doses of 4, 6 or 8 pg/kg/min on three separate trial days.
Study: NCT03345862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: non-pharmacological multicomponent
Description: Following the proposal of Nicholson \& Shellman, (2013) collected in its CARELINK program, an intervention is proposed that includes: 6 sessions at home \[30-60 minutes\] for 16 weeks (1 fortnightly session) and 5 telephone sessions \[20 min.\] That will be intercalated (in the 16 weeks) depending on the particular characteristics of each person. The first visit, aimed at defining objectives and creating a relationship of trust for future visits.
Study: NCT00179010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: Adenosine intrarterial (intrabrachial) infusion at 3 diferent doses for 15 minutes each

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: Adenosine intrarterial (intrabrachial) infusion at 3 diferent doses for 15 minutes each

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine Mono Phosphate (AMP)
Description: Intraterial infusion of AMP at 3 different doses for 15 minutes each (at equimolar doses as adenosine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine Mono Phosphate (AMP)
Description: Intraterial infusion of AMP at 3 different doses for 15 minutes each (at equimolar doses as adenosine)
Study: NCT01942655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample and recto-colic biopsies
Study: NCT01327937

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Apligraf
Description: Apligraf group - Applied at Day 0, Weeks 1-4 (maximum of 5 applications) Also cross-over at Week 4 for Control NPTH group - Apligraf applied at Week 4, Weeks 5-8 (maximum of 5 applications)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care Dressing Group
Description: Standard dressing regimen - Foam dressing (eg, Mepilex) and 4 layered compression system (eg, Profore)
Study: NCT00432861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PANCRECARB® (pancrelipase)
Description: Capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules
Study: NCT04127305

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT03019458

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MINGO
Description: 6 20oz sachets will be taken daily by intervention group
Study: NCT06283602

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: oral health status
Description: the dentists examined the dried teeth with a probe and mount mirror in a dental unit.
Study: NCT02278796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BeEAM
Description: Chemotherapy regimen consisting of bendamustine intravenously on days -7 and -6 at 200 mg/m2; cytarabine, 400 mg/m2 intravenously daily from day -5 to day-2; etoposide, 200 mg/m2 intravenously daily from day -5 to day -2; and melphalan, 140 mg/m2 intravenously on day -1 before reinfusion of autologous stem cells

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BEAM
Description: Chemotherapy regimen with carmustine (BCNU) 300 mg/m2 on day -6, cytarabine, 400 mg/m2 intravenously daily from day -5 to day-2; etoposide, 200 mg/m2 intravenously daily from day -5 to day -2; and melphalan, 140 mg/m2 intravenously on day -1 before reinfusion of autologous stem cells
Study: NCT00021398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT00997243

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lintuzumab
Description: Cycle 1 600mg as an IV infusion (flat dose for all), given on days 2, 7, 15, and 22. Subsequent Cycles (cycles to be repeated every 28 days) 600mg as an IV infusion, given every other week, twice during each cycle, including one dose given during AZA therapy. Doses should be given at least 12 days apart. By convention, dosing on days 7 and 22 of each cycle will be encouraged, but due to expected issues of patient convenience (time, travel, etc.), the study requirements are every other week, twice during each cycle, with one dose during AZA treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-azacytidine
Description: 75mg/m2 IV/SC daily on days 1-7.
Study: NCT02521259

Intervention type: DEVICE
Intervention: BIS
Description: BIS monitoring provides the patient's depth of consciousness, enables us to monitor safe, optimal anesthesia for each patient.

Intervention type: DEVICE
Intervention: BIS
Description: BIS monitoring provides the patient's depth of consciousness, enables us to monitor safe, optimal anesthesia for each patient.
Study: NCT03330119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alternate Management
Description: With the alternate management protocol, the pre-operative order set is the same, with the addition of a single preoperative dose of acetaminophen 1 g IV x1, gabapentin 600 mg PO x1, and ondansetron 8 mg IV x1. Post-operatively, patients receive the same ketorolac 30mg x 9 doses every 6 hours, as well as acetaminophen 975 mg every 6 hours, both given standing. These two are timed so the patient is receiving one of the two medications every 3 hours during their inpatient stay. After 9 doses of ketorolac, the patient receives 600mg of ibuprofen PO, also given standing, instead of the ketorolac. If the patient requires narcotics, they may receive them on an as needed basis. IV fluids are running at 80 cc/ hour. Patients are encouraged to ambulate, including the evening of the surgery, have their foley catheter removed 12 hours post-operatively, and can have a regular diet immediately.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The regular Lankenau cesarean section order set includes routine vital signs, labs, IV fluids, and fetal heart monitoring. Post standard cesarean section orders include IV fluids running at 125 cc/ hour, along with routine post-partum care. In terms of pain control, most patients receive 9 doses of 30mg of IV ketorolac every 6 hours, along with hydromorphone, oxycodone/acetaminophen, or a hydromorphone PCA, per patient or attending request.
Study: NCT03774992

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthokeratology lenses
Description: Custom fit, form stable contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthokeratology lenses
Description: Custom fit, form stable contact lenses
Study: NCT03841344

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Evaluation of the utility of candidate endpoints in PAH trials

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Evaluation of the utility of candidate endpoints in PAH trials

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Evaluation of the utility of candidate endpoints in PAH trials

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Evaluation of the utility of candidate endpoints in PAH trials
Study: NCT02460471

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: palliative radiation therapy
Description: thermoplastic mask immobilization. CT in treatment position. radiation dose of 25 Gy in 5 daily fractions over one week 6 MV photons by intensity modulation. Target volume is the symptomatic tumour volume with a 5 mm margin
Study: NCT02949518

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery Pathway (ERP) for Spine
Description: The study team emphasizes that all components of the ERP are considered standard of care at this institution. The objective of this study is to ensure that the study patients assigned to the ERP will receive these standard of care components.
Study: NCT04073823

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexitouch Plus
Description: Flexitouch Plus full arm and core treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexitouch Plus FT with software modification
Description: Flexitouch Plus full arm and trunk/chest treatment
Study: NCT04390815

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Description: Adding insulin to conventional wound treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Adding insulin to conventional wound treatment
Study: NCT03391167

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided erector spinae plane block
Description: A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to T9 spinous process. The erector spinae muscles will be identified superficial to the tip of T9 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.375% bupivacaine will be injected (maximum of 3mg/kg).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Pain Followup and Monitorization
Description: Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Pain Followup and Monitorization
Description: Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
Study: NCT06309303

Intervention type: OTHER
Intervention: Clinical evaluation
Description: Evaluation of clinical manifestation, laboratory ad imaging testing results, disease course, treatment and outcome

Intervention type: OTHER
Intervention: Clinical evaluation
Description: Evaluation of clinical manifestation, laboratory ad imaging testing results, disease course, treatment and outcome
Study: NCT00123513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Environmental changes in the food and physical activity environment. Cafeteria and vending machine changes, food brought from home, walking routes, and awareness building.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Increase routing physical activity, walking routes, stairs intervention, etc.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Environment
Description: Cafeteria and vending machine changes and identification of opportunities of physical activity.
Study: NCT01567163

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: ramucirumab 10 milligrams/kilogram (mg/kg) intravenous infusion, administered on Day 1 of 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: docetaxel 75 milligrams/square meter (mg/m\^2) intravenous infusion administered on Day 1 of each 3-week cycle
Study: NCT03142217

Intervention type: OTHER
Group type: OTHER
Intervention: Study of dysarthria in patients with Huntington's disease
Description: Study of dysarthria in patients with Huntington's disease
Study: NCT04499040

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Blood sample
Description: Blood samples to assess biological parameters such as:

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood samples to assess biological parameters such as:

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fecal samples
Description: Microbiota analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal samples
Description: Microbiota analysis

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological
Description: Neuropsychological assessment
Study: NCT04266743

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FeetMe Monitor
Description: For gait parameters' evaluation, the investigator asks the participant to move in a straight line over a 10-meter mat. The participant had to start the feet in line and then start walking at a comfortable speed. During this time, the investigator records the gait parameters from the FeetMe Monitor® and Gaitrite® system.~An operator asked the patient to repeat 3 trials. The same sequence was repeated by three other operators. The same measurement is done 7 days later.~A questionnaire is given to assess the ergonomics of the device
Study: NCT01177813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo identical to BI10773 high dose
Description: placebo tablets once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 low dose tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 open label
Description: Patients receive BI 10773 high dose tablets open label once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo identical to BI10773 low dose
Description: placebo tablets once daily
Study: NCT02173964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pinaverium bromide
Description: pinverin 50 mg per oral single dose versus simple water ingestion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: water
Description: same amount of water for pinverin administration
Study: NCT01496118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib
Description: Specified dose on specified days
Study: NCT01177813

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo identical to BI10773 low dose
Description: placebo tablets once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo identical to BI10773 high dose
Description: placebo tablets once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo identical to Sitagliptin 100mg
Description: placebo tablets once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo identical to Sitagliptin 100mg
Description: placebo tablets once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI10773
Description: BI 10773 high dose tablets once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin tablets 100 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo identical to Sitagliptin 100mg
Description: placebo tablets once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo identical to BI10773 low dose
Description: placebo tablets once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo identical to BI10773 high dose
Description: placebo tablets once daily
Study: NCT02147860

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diabetes Assistant (DiAs) with USS Virginia
Description: DiAs is the central component of our system. It is a standard cell phone running on an Android operating system. The cell phone has been changed to prevent from (1) using it as a phone or browser, (2) changing the volume (3) accidentally shutting it off. The cell phone runs an algorithm and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range and help avoid hypoglycemia during the night.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sensor Augmented Pump Therapy
Description: Subjects randomized to this placebo group will wear a continuous glucose monitoring system (CGM) to measure sensor glucose and a physiological monitor to measure heart rate and 3-axis accelerometer for 24-72 hours.
Study: NCT01521949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acai Juice Product
Description: 2 ounces of Acai Juice Product twice daily.
Study: NCT03413371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: in group P patients will receive pre-emptive analgesia using intravenous infusion of acetaminophen in a single dose of 10-15 mg per kg of body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: in group P patients will receive pre-emptive analgesia using intravenous infusion of acetaminophen in a single dose of 10-15 mg per kg of body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: in group P patients will receive pre-emptive analgesia using intravenous infusion of acetaminophen in a single dose of 10-15 mg per kg of body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: in group P patients will receive pre-emptive analgesia using intravenous infusion of acetaminophen in a single dose of 10-15 mg per kg of body weight
Study: NCT04086303

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LSST test
Description: LSST test: Scapular mobility testing Upper Extremity test: Upper extremity agility and endurance testing Y Balance test: Balance and Coordination testing Sit and Reach Test: Assessment of flexibility

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LSST test
Description: LSST test: Scapular mobility testing Upper Extremity test: Upper extremity agility and endurance testing Y Balance test: Balance and Coordination testing Sit and Reach Test: Assessment of flexibility
Study: NCT02004652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: Prucalopride, 2mg, tablet. First given 24 hours after surgery beginning on POD 1,until bowel movements or for a maximum of 7 days of postoperative treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vitamin, 50mg, tablet.
Study: NCT01650779

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Agalsidase beta
Description: Commercially available agalsidase beta 1.0 mg/kg administered as an intravenous infusion q2w up to Month 6.